Funding news · Nov 12, 2026

Orakl Oncology Raises $34M Series A Led by Norrsken VC

Orakl Oncology Closes $34M Series A

Orakl Oncology, a developer of a drug-testing platform for oncology, has raised $34 million in Series A funding. The round was led by Norrsken VC.

What Orakl Oncology Does

Orakl Oncology builds a drug-testing platform that models how cancer patients respond to therapies. The platform uses patient-derived biology to create virtual representations of tumors. Pharmaceutical teams use it to predict treatment response and de-risk oncology development programs before human trials.

Funding Details

  • Round: Series A
  • Amount: $34 million USD
  • Lead Investor: Norrsken VC
  • Date: November 12, 2026

Investor Syndicate

The Series A included participation from a broad group of investors:

  • InfraVia
  • Bpifrance
  • Speedinvest
  • Verve Ventures
  • Serena (lead, via InnovAllianz III)
  • Plug and Play Tech Center
  • Norrsken VC
  • Singular
  • HCVC
  • Teampact Ventures

Strategic Context

The Series A provides Orakl Oncology with capital to advance its patient-derived tumor modeling platform. By enabling pharmaceutical teams to predict treatment response before human trials, the company addresses a key challenge in oncology drug development: reducing the risk and cost of late-stage failures.

For acquisition-oriented observers, Orakl Oncology represents a platform positioned at the intersection of computational biology and oncology drug development, with a syndicate that includes both European and international investors.

© 2026 VeilStrat. All rights reserved.All systems operational